



**Florida Department of Health  
Public Health Statistics and Performance Management  
Institutional Review Board**

**Meeting Details**

<b>Date:</b> 2/23/2026	<b>Time of Meeting Called to Order: 1:31 PM</b> <b>Time of Meeting End: 1:59 PM</b>	<b>Location:</b> Microsoft Teams
<p><b>Purpose:</b> To conduct &amp; review new research studies involving human participants, modifications to existing studies, and continuing review of ongoing research to ensure research studies comply with regulations per the Department's ethical standards.</p>		<p><b>Meeting Summary by:</b> Victoria Creel, IRB Coordinator</p>

IRB Member Attendees	Status	Affiliated (Y/N)	Method of Attendance	If alternate, name of regular member substituted; reason for substitution
Sandra Schoenfisch, PhD, MS, BSN, RN	Chair, Subpart D: Children Representative, Scientific	N	Teams	
Merlene Ramnon, PhD, MPH, MSN, BSN (joined at 1:36 PM)	Chair, Scientific	Y	Teams	
Adrian Cooksey, DrPH, MPH	Scientific	Y	Teams	
Susan Bulecza, DNP	Scientific	N	Teams	
Vincent Edwards	Non-Scientific	Y	Teams	
Nina Mattei, MS	Scientific	Y	Teams	
Meredith Hennon, MPH	Scientific	Y	Teams	
Gladys Liehr, Dr. rer. Nat.*	Scientific	Y	Teams	

Prince Danso-Odei, MD, DrPH, MPH	Scientific	N	Absent	
Julia Fashner, MPH, MD, MS*	Scientific	N	Absent	
Victoria Creel	IRB Coordinator		Teams	
Bridgette Morton	Deputy Director, Public Health Research		Teams	

Number of Members on Roster	Number of Members Required for Quorum	Is Quorum Met?
10	6	Yes

## Conflict of Interest Attestation

IRB Members were asked if there were any conflicts of interest and, if so, to recuse themselves from the meeting, or from voting on the applicable study.

## Business Items

The following business items were discussed during the IRB Committee Meeting.

1. Introductions
2. Outstanding reviews – committee members were reminded to complete their assigned reviews.
3. Site visit update – AAHRPP has 30 days from the site visit to provide the report. The report has not been provided yet.
4. CITI certifications – please review certifications and make sure they are up to date. If renewal is needed, please send completed certification to Victoria Creel.
5. Meeting minutes – at 1:39 PM, Dr. Bulecza made a motion to approve, which was seconded by Dr. Schoenfisch. Minutes are approved by the committee with eight ayes.
6. Bylaws draft– committee members were sent a draft of bylaws written by Victoria Creel prior to the meeting. They were asked to provide feedback or edits. No changes were requested, so a draft is being routed through the Division of Public Health Statistics and Performance Management for approval before being voted on by the committee.
7. Next meeting date – Victoria Creel will send out a survey to committee members to pick a date.
8. Term limits and recruitment – Most committee members have stayed on past their term ending. Victoria Creel will work with Bridgette Morton and Dr. Brooks to see if there are recruitment ideas and succession plans. Some suggestions are recruiting through the County Health Department call or sending a message to bureau chiefs and division directors for possible nominations.

## Submissions for Convened Board Review

<b>Protocol Title:</b>	Clofazimine use in the long-term treatment of leprosy, Phase 3 (Florida Department of Health) (2006-02)					
<b>Submission:</b>	<b>Principal Investigator:</b>		<b>Presenters:</b>			
<b>Continuing Review</b>	<b>David Ashkin, MD</b>		<b>Sandra Schoenfisch, PhD, MS, BSN, RN Susan Bulecza, DNP</b>			
<b>Effective Date of Approval:</b>	<b>Approval on 2/23/2026</b>					
<b>Approval Period:</b>	<b>12 months</b>					
<b>Level of Risk:</b>	<b>Greater than minimal risk</b>					
<b>Funding Source, if applicable:</b>	<b>NA</b>					
<b>Grant Name, if applicable:</b>						
<b>IND or IDE, if applicable:</b>	<b>IND</b>					
<b>Documents Reviewed and Notes:</b>	<p>Continuing review. Ongoing study since 2005; treatment for multi-drug-resistant tuberculosis that has been ongoing. It is very limited use. Reviewers see no problem with this study. Only around 129 patients have been enrolled in the study since its inception. This is standard treatment for patients with this disease. The potential for complications with the medication is very low. The medication is not readily available for use in the United States, so it runs under an IND.</p> <p>At 1:47 PM, motion to approve made by Dr. Bulecza, seconded by Dr. Schoenfisch, all members present (8 members) voted 'aye'. No abstentions or substitutions.</p>					
<b>Controverted Issues, if applicable:</b>						
<b>Informed Consent Forms Reviewed?</b>			<b>Informed Consent Forms Meet Regulatory Requirements?</b>			
<input checked="" type="checkbox"/>			<input checked="" type="checkbox"/>			
<b>Motion:</b>						
Approved	Approved with Stipulations	Conditions Pending for Approval	Disapproved	Tabled	Tabled Assistance	Terminated
<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Voting:</b>						
For:	Against:	Abstain:	Recused:	Substitutions:		
8	0	0	0	N/A		

## Acknowledgement for Closure

For informational purposes only

<b>Protocol Title:</b>	WIC ITFPS-2: Feeding My Baby – A National WIC Study (2013-06-Westat-WST)	
<b>Submission:</b>	<b>Principal Investigator:</b>	<b>Presenters:</b>
Place on agenda for acknowledgement of Closure	Borger, Christine Ph.D	None

<b>Protocol Title:</b>	Developing the evidence base for overdose policies: a multilevel analysis of NHBS (2021-450-DFT)	
<b>Submission:</b>	<b>Principal Investigator:</b>	<b>Presenters:</b>
Place on agenda for acknowledgement of Closure	Cooper, Hannah PhD	None

<b>Protocol Title:</b>	Comparative effectiveness of Juntos Después del Cáncer (JDC) among Breast Cancer Survivors and their Intimate Partners	
<b>Submission:</b>	<b>Principal Investigator:</b>	<b>Presenters:</b>
Place on agenda for acknowledgement of Closure	Martinez Tyson, Dinorah PhD	None

At 1:59 PM, motion to adjourn made by Dr. Schoenfisch, seconded by Dr. Liehr, all members present (8 members) voted 'aye'.